Melanoma Response Articles & Analysis
9 news found
The Phase 2 study is designed to assess whether the addition of SCIB1 to pembrolizumab (Keytruda®) will result in an improvement in the tumour response rate, progression-free survival and overall survival in patients with advanced melanoma, who are also eligible for treatment with pembrolizumab. ...
ByScancell
Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the publication of a paper on personalized therapy with EVX-01 in patients with metastatic melanoma in the open access, peer-reviewed journal OncoImmunology. ...
“The data we continue to generate in the Phase 1 SURPASS trial shows promising responses for patients across multiple solid tumor indications. We will continue to explore more next-gen enhancements and manufacturing improvements, informed by our ongoing translational research, to deliver the best cell therapies we can for people with cancer.” Addition of AKTi during ...
He gave the example of the company's work in cancer immunotherapy. "When you have a good response to an immunotherapy or combination therapy, something is happening in your immune cells that is leading to that good immune response and killing of the tumor," he said. ...
ByImmunai
Though skin cancer risks exist all year long, the dangers are even greater during the summer months, when the days are longer, and more people are outside for longer periods of time. The rate of new melanoma diagnoses—responsible for 75% of all skin cancer deaths—was 23% higher in Delaware than the national average from 2002-2006 and was the 9th ...
Though skin cancer risks exist all year long, the dangers are even greater during the summer months, when the days are longer, and more people are outside for longer periods of time. The rate of new melanoma diagnoses—responsible for 75% of all skin cancer deaths—was 35% higher in Washington than the national average from 2001-2005 and was the 5th ...
Though skin cancer risks exist all year long, the dangers are even greater during the summer months, when the days are longer, and more people are outside for longer periods of time. The rate of new melanoma diagnoses—responsible for 75% of all skin cancer deaths—was 36% higher in Oregon than the national average from 2002-2006 and was the 4th highest ...
Though skin cancer risks exist all year long, the dangers are even greater during the summer months, when the days are longer, and more people are outside for longer periods of time. The annual rate of new melanoma diagnoses—responsible for 75% of all skin cancer deaths—was 34% higher in Idaho than the national average and was the 7th highest in the ...
Melanoma is now one of the most common cancers among young adults ages 15 to 29. The rate of new melanoma diagnoses – responsible for 75% of skin cancer deaths – has increased by about 5% per year among New Jersey residents from the early 1990s to 2006. ...